Match the named sequence and route
FDA identifies limited safety information and peptide-related impurity concerns for Semax. A modified analogue or another delivery route should not be treated as the same studied preparation.
Documentation to request
Ask for full identity, modification status and formulation details. Compare vial and spray documentation separately rather than transferring claims between them.
Regulatory context: FDA: substance-specific safety concerns. Source reviewed . This source does not verify the identity, testing or availability of our catalog references.
Related guidance: Non-clinical protocol review checklist. These references support a review, not a treatment recommendation or supply authorization.